Bristol-Myers Squibb Company company logo

# RNN 1st Gen Model Bristol-Myers Squibb Company Pharmaceutical preparations

Prediction models:
71.88% successful of 32 deals
$ 52.71 Last close price
at 18-may-2018

BMY

Model's trade recommendations No return for period yet

-1.03% Annual return

$84.18B Market Cap

β 0.99  

BMY

Model (following trade recommendations)

BMY

Underlying stock

S&P 500

Index
Return for period
3.56%
1.78%
52wk return 7.23%
-2.43%
16.82%
52wk Range
50.53—68.98
2000.54—2399.63
Sortino ratio -0.21
Sharpe ratio -0.18
Norm. RMSE 1.31%
Downside risk 5.58%
Volatility 6.40%
  • 1.60 (3.11%) Div (Yield)
  • BUY Analysts consensus recommendation

Bristol-Myers Squibb is a differentiated company, led by their unique BioPharma strategy that leverages the reach and resources of a major pharma company paired with the entrepreneurial spirit and agility of a biotech firm. They work every day to deliver innovative medicines for patients with serious and life-threatening diseases. Their employees around the world work together for patients - it drives everything they do. They are focused on helping millions of patients around the world in disease areas such as oncology, cardiovascular, immunoscience and fibrosis. Through their R&D organization, they have built a sustainable pipeline of potential therapies, and actively partner to access external innovation to broaden and accelerate their work.

Industry sector: Medical

Sector classification: Pharmaceutical preparations

Deep Learning based analysis and prediction model for Bristol-Myers Squibb Company (BMY) stock is a 1st Generation Non-linear Autoregresive with exogenous variable(s) (NARX) model based on the Recurrent Neural Network architecture.

Model is in the production pipeline since Oct. 2, 2015.

Market data for BMY model training are being downloaded from the Quandl premium datasets on a daily basis.

Model is being retrained on a daily basis.

Float 1631M
P/E 16.56
Shares Outstanding 1635M
% Held by Insiders 0.23%
% Held by Institutions 71.69%
EPS (last reported FY) $3.01
EPS (last reported Q) $0.94
EPS, estimated (last reported Q) $0.85
Total revenues $21 B
Net income $1 B